Co-Development with SUSMED,Inc. of a Therapeutic App in Otolaryngology
First written in FY2023-Q2. 7 of 11 entries say "Advanced", first in FY2023-Q3. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「A confirmatory study of the tinnitus treatment app KRP-DT123 has begun.」
KRP-DT123 progressed from the specified clinical research that began in September 2023 to the start of a confirmatory study. - FY2026-H1AdvancedAnnual report
「The physician-initiated specified clinical research using the DTx tinnitus treatment app KRP-DT123 produced favorable results, including achievement of its primary endpoint.」
KRP-DT123 progressed from the continuation of specified clinical research to results achieving the primary endpoint. - FY2025-H1RestatedAnnual report
「Regarding progress in domestic and overseas development during the interim consolidated accounting period, there were no transitions between clinical-trial phases, but the respective trials for KRP-R120, a treatment for interstitial lung disease, and KRP-114VP, a treatment for overactive bladder (the paediatric indication of Beova), as well as the specified clinical research study for KRP-DT123, an app for treating tinnitus, are progressing steadily.」
Development, including specified clinical research on KRP-DT123, is continuing, but no new phase transition has been documented. - FY2024RestatedAnnual report
「Specified clinical research conducted by a medical institution on the tinnitus treatment app KRP-DT123 also began in September 2023.」
For KRP-DT123, the specified clinical research conducted by a medical institution that began in September 2023 continues to be documented. - FY2024-Q3RestatedAnnual report
「Specified clinical research conducted by a medical institution on the tinnitus treatment app KRP-DT123 also began in September 2023.」
The initiative with サスメド involving a therapeutic app for the otolaryngology field continues to document the specified clinical research that began in September 2023. - FY2024-Q2AdvancedAnnual report
「Specified clinical research conducted by a medical institution on the therapeutic app KRP-DT123, which is being developed by Kyorin Pharmaceutical Co., Ltd., began in September 2023.」
The initiative with サスメド involving a therapeutic app for the otolaryngology field progressed from the preparation stage for specified clinical research to the start of the study in September 2023. - FY2024-Q1AdvancedAnnual report
「治療用アプリ「KRP-DT123」の特定臨床研究の準備」
The initiative with サスメド involving a therapeutic app for the otolaryngology field progressed to the preparation stage for specified clinical research on KRP-DT123. - FY2023-Q3AdvancedAnnual report
「当第３四半期連結会計期間における開発パイプラインの拡充としては、2022年11月に杏林製薬㈱がサスメド㈱と耳鼻科領域における治療用アプリの共同研究開発及び販売に関する契約を締結しました。当社グループは、耳鼻科領域を重点領域としており、特定の耳鼻科疾患に対する新たな治療選択肢の提供を目指し、治療用アプリの開発に着手しました。」
サスメドとの耳鼻科領域治療用アプリ契約の締結に加え、特定疾患向けの開発着手まで進展した。 - FY2023-Q2First statedAnnual report
「Domestic co-development; contracting company: KYORIN Pharmaceutical Co.,Ltd. (consolidated subsidiary); product: therapeutic app in otolaryngology; counterparty: SUSMED,Inc.; contract year: 2022.」
A new co-development agreement with SUSMED,Inc. for a therapeutic app in otolaryngology was disclosed as of the filing date.